Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice

European Journal of Pharmacology

Volumn 346, Issue 1, 1998, Pages 23-33

  Decker, Michael W ^a   Bannon, Anthony W ^a   Buckley, Michael J ^a   Kim, David J B ^a   Holladay, Mark W ^a   Ryther, Keith B ^a   Lin, Nan Horng ^a   Wasicak, James T ^a   Williams, Michael ^a   Arneric, Stephen P ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

Antinociception; Anxiety; Locomotor activity; Nicotinic acetylcholine receptor

Indexed keywords

5 (2 AZETIDINYLMETHOXY) 2 CHLOROPYRIDINE; ALCOHOL; HEXAMETHONIUM; MECAMYLAMINE; MORPHINE SULFATE; NALTREXONE; NICOTINIC AGENT; PENTOBARBITAL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG POTENTIATION; EXPLORATORY BEHAVIOR; HOT PLATE TEST; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MAZE TEST; MOUSE; NONHUMAN; ORAL DRUG ADMINISTRATION; PAIN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY; WRITHING TEST;

ANALGESICS, NON-NARCOTIC; ANIMALS; AZETIDINES; HEXAMETHONIUM; LETHAL DOSE 50; MALE; MAZE LEARNING; MECAMYLAMINE; MICE; MORPHINE; MOTOR ACTIVITY; NALTREXONE; NARCOTIC ANTAGONISTS; NEURONS; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PAIN; PYRIDINES;

EID: 0032478589     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(98)00042-9     Document Type: Article

References (38)

1. Aceto M.D., Awaya H., Martin B.R., May E.L. Antinociceptive action of nicotine and its methiodide derivatives in mice and rats. Br. J. Pharmacol. 79:1983;869-876.
2. Arneric S.P., Sullivan J.P., Briggs C.A., Donnelly-Roberts D., Anderson D.J., Raszkiewicz J.L., Hughes M.L., Cadman E.D., Adams P., Garvey D.S., Wasicak J.T., Williams M. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition-enhancing and anxiolytic activities: I. In vitro characterization. J. Pharmacol. Exp. Ther. 270:1994;310-318.
3. Badio B., Daly J.W. Epibatidine, a potent analgetic and nicotinic agonist. Mol. Pharmacol. 45:1994;563-569.
4. Bannon A.W., Gunther K.L., Decker M.W. Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (±)-epibatidine. Pharmacol. Biochem. Behav. 51:1995;693-698.
5. Bannon A.W., Gunther K.L., Decker M.W., Arneric S.P. The influence of Bay K 8644 treatment on (±)-epibatidine-induced analgesia. Brain Res. 678:1995;244-250.
6. Bannon A.W., Decker M.W., Holladay M.W., Curzon P., Donnelly-Roberts D., Puttfarcken P.S., Bitner R.S., Diaz A., Dickenson A.H., Williams M., Arneric S.P. Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science. 279:1998;77-81.
7. Bannon, A.W., Decker, M.W., Curzon, P., Buckley, M.J., Kim, D.J.B., Radek, R.J., Lynch, J.K., Wasicak, J.T., Arnold, W.H., Holladay, M.W., Arneric, S.P., 1998b. ABT-594 [5-((2R)-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors. II. In vivo characterization. J. Pharmacol. Exp. Ther., in press.
8. Bonhaus D.W., Bley K.R., Broka C.A., Fontana D.J., Leung E., Lewis R., Shieh A., Wong E.H.R. Characterization of the electrophysiological, biochemical and behavioral actions of epibatidine. J. Pharmacol. Exp. Ther. 272:1995;1199-1203.
9. Brioni J.D., O'Neill A.B., Kim D.J.B., Decker M.W. Nicotinic receptor agonists exhibit anxiolytic-like effects on the elevated plus-maze. Eur. J. Pharmacol. 238:1993;1-8.
10. Brioni J.D., O'Neill A.B., Kim D.J.B., Buckley M.J., Decker M.W., Arneric S.P. Anxiolytic-like effects of the novel cholinergic channel activator ABT-418. J. Pharmacol. Exp. Ther. 271:1994;353-361.
11. Collier H.O.J., Dinneen L.C., Johnson C.A., Schneider C. The abdominal constriction response and its suppression by analgesic drugs in the mouse. Br. J. Pharmacol. Chemother. 32:1968;295-310.
12. Collins A.C., Evans C.B., Miner L.L., Marks M.J. Mecamylamine blockade of nicotinic responses: evidence for two brain nicotinic receptors. Pharmacol. Biochem. Behav. 24:1986;1767-1773.
13. Damaj M.I., Creasy K.R., Grove A.D., Rosecrans J.A., Martin B.R. Pharmacological effects of epibatidine optical enantiomers. Brain Res. 664:1994;34-40.
14. Damaj M.I., Creasy K.R., Welch S.P., Rosecrans J.A., Aceto M.D., Martin B.R. Comparative pharmacology of nicotine and ABT-418, a new nicotinic agonist. Psychopharmacology. 120:1995;483-490.
15. Decker M.W., Brioni J.D., Sullivan J.P., Buckley M.J., Radek R.J., Raskiewickz J.L., Kang C.H., Kim D.J.B., Giardina W.J., Williams M., Arneric S.P. (S)-3-methyl-5-(1-methyl-2-pyrrolidinyl) isoxazole (ABT 418): a novel cholinergic ligand with cognition enhancing and anxiolytic activities: II. In vivo characterization. J. Pharmacol. Exper. Ther. 270:1994;319-328.
16. Decker M.W., Buckley M.J., Brioni J.D. Differential effects of pretreatment with nicotine and lobeline on nicotine-induced changes in body temperature and locomotor activity in mice. Drug Devel. Res. 31:1994;52-58.
17. Decker M., Brioni J., Bannon A., Arneric S. Diversity of neuronal nicotinic acetylcholine receptors: lessons from behavior and implications for CNS therapeutics. Life Sci. 56:1995;545-570.
18. Decker M.W., Bannon A.W., Curzon P., Gunther K.L., Brioni J.D., Holladay M.W., Lin N.-H., Li Y., Daanen J.F., Buccafusco J.J., Prendergast M.A., Jackson W.J., Arneric S.P. ABT-089[2-methyl-3-(2-(s)-pyrrolidinylmethoxy)pyridine dihydrochloride]: II. A novel cholinergic channel modulator with effects on cognitive performance in rats and monkeys. J. Pharmacol. Exp. Ther. 283:1997;247-258.
19. Donnelly-Roberts, D.L., Puttfarcken, P.S., Kuntzweiler, T.A., Briggs, C.A., Anderson, D.J., Campbell, J.E., Manelli, A., Piatonni-Kaplan, M., McKenna, D.G., Wasicak, J.T., Holladay, M.W., Williams, M., Arneric, S.P., 1998. ABT-594 ((R)-5-(2-Azetidinylmethoxy)-2-Chloropyridine): I. In vitro profile of a novel analgesic neuronal acetylcholine (nAChR) ligand. J. Pharmacol. Exp. Ther., in press.
20. Holladay M.W., Wasicak J.T., Lin N.H., He Y., Ryther K.B., Bannon A.W., Buckley M.J., Kim D.J.B., Decker M.W., Anderson D.J., Campbell J.E., Kuntzweiler T.A., Donnelly-Roberts D.L., Piattoni-Kaplan M., Briggs C.A., Williams M., Arneric S.P. Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent orally active non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. J. Med. Chem. 41:1998;407-412.
21. Insel, P.A., 1996. Analgesic-antipyretic and antiinflammatory agents and drugs employed in the treatment of gout. In: Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., Gilman, A.G. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn., McGraw-Hill, New York, pp. 617-657.
22. Li T., Qian C., Eckman J., Huang D.F., Shen T.Y. The analgesic effect of epibatidine and isomers. Bioorg. Med. Chem. Lett. 3:1993;2759-2764.
23. Lin N.-H., Gunn D.E., Ryther K.B., Garvey D.S., Donnelly-Roberts D.L., Decker M.W., Brioni J.D., Buckley M.J., Rodrigues A.D., Marsh K.G., Anderson D.J., Buccafusco J.J., Prendergast M.A., Sullivan J.P., Williams M., Arneric S.P., Holladay M.W. Structure-activity studies on 2-methyl-3-(2-(S)-pyrrolidinylmethoxy) pyridine (ABT-089): an orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor (nAChR) ligand with cognition enhancing properties. J. Med. Chem. 40:1997;385-390.
24. Luetje C.W., Patrick J., Séguéla P. Nicotine receptors in the mammalian brain. FASEB J. 4:1990;2753-2760.
25. Pauli P., Rau H., Zhuang P., Brody S., Birbaumer N. Effects of smoking on thermal pain threshold in deprived and minimally-deprived habitual smokers. Psychopharmacology. 111:1993;472-476.
26. Pellow S., Chopin P., File S.E., Briley M. Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J. Neurosci. Meth. 14:1985;149-167.
27. Perkins K.A., Grobe J.E., Stiller R.L., Scierka A., Goettler J., Reynolds W., Jennings J.R. Effects of nicotine on thermal pain detection in humans. Exp. Clin. Psychopharmacol. 2:1994;95-106.
28. Pomerleau O.F. Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharm. Bull. 22:1986;865-869.
29. Qian C., Li T., Shen Y.T., Libertine-Garahan L., Eckman J., Biftu T., Ip S. Epibatidine is a nicotinic analgesic. Eur. J. Pharmacol. 250:1993;R13-R14.
30. Rao T.S., Correa L.D., Reid R.T., Lloyd G.K. Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (nAChR) ligands in the rat tail-flick assay. Neuropharmacology. 35:1996;393-405.
31. Reisine, T., Pasternak, G., 1996. Opioid analgesics and antagonists. In: Hardman, J.G., Limbird, L.E., Molinoff, P.B., Ruddon, R.W., Gilman, A.G. (Eds.), Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th edn., McGraw-Hill, New York, pp. 521-555.
32. Sahley T.L., Berntson G.G. Antinociceptive effects of central and systemic administrations of nicotine in the rat. Psychopharmacology. 65:1979;279-283.
33. Sargent P.B. The diversity of neuronal nicotinic acetylcholine receptors. Annu. Rev. Neurosci. 16:1993;403-443.
34. Spande T.F., Garraffo H.M., Edwards M.W., Yeh H.J.C., Pannell L., Daly J.W. Epibatidine: a novel (chloropyridyl)azabicycloheptane with potent analgesic activity from an Ecuadorian poison frog. J. Am. Chem. Soc. 114:1992;3475-3478.
35. Sullivan J., Decker M.W., Brioni J.D., Donnelly-Roberts D., Anderson D.J., Bannon A.W., Kang C., Adams P., Piattoni-Kaplan M., Buckley M.J., Gopalakrishnan M., Williams M., Arneric S.P. (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. J. Pharmacol. Exp. Ther. 271:1994;624-631.
36. Sullivan J.P., Donnelly-Roberts D., Briggs C.A., Anderson D.J., Gopalakrishnan M., Xue I.C., Piattoni-Kaplan M., Molinari E., Campbell J.E., McKenna D.G., Gunn D., Lin N., Ryther K., He Y., Holladay M.W., Wonnacott S., Williams M., Arneric S.P. ABT-089[2-methyl-3-(2-(s)-pyrrolidinylmethoxy)pyridine dihydrochloride]: I. A potent and selective cholinergic channel modulator with neuroprotective properties. J. Pharmacol. Exp. Ther. 283:1997;235-246.
37. Tripathi H.L., Martin B.R., Aceto M.D. Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. J. Pharmacol. Exp. Ther. 221:1982;91-96.
38. Woolfe G., MacDonald A.D. The evaluation of the analgesic action of pethidine hydrochloride (Demerol). J. Pharmacol. Exp. Ther. 80:1944;300-307.